This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
mCRPC in focus

Transcript: Can investigational treatments address unmet needs in mCRPC?

Last updated:4th Sep 2024
Published:4th Sep 2024

Professor Axel Merseburger

All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

So, the question is, "What are the emerging pharmacological strategies that could help meet unmet needs in mCRPC?" And so far, let's have a look at the treatment, what we do.

We give hormone treatment or we give chemotherapy, as for most of the patients we treat. And then, we have a small percentage which are biomarker positive, namely BRCA1, or BRCA2, or ATM. For them, we have approved PARP inhibitors as treatment options. So, the question is, does biomarker analysis the status, whether it's a liquid biopsy or a tissue, it's not always as that easy, especially in private practices, in smaller hospitals. And here, for the future, possibly, possibly combinations or treatments that don't need or are not depending on the biomarker status and basically offer a benefit for a broad patient population in an all-comer population.

I think this would be the goal for us as treating physicians, and also for the patients that we know. Regardless of the biomarker status, there is a benefit for the man with this deadly mCRPC disease. Aside, novel clinical trial investigations for the treatment as first-line treatment in mCRPC are on the horizons, including immunotherapy. And I'm personally really much looking forward to the next large congresses and publications on the results on mCRPC first, second, and third-line treatment.

View the video

Welcome: